Development and performance of an enzyme immunoassay to detect creatine kinase isoenzyme MB activity using anti-mitochondrial creatine kinase monoclonal antibodies

Hoshino, Tadashi; Sakai, Yasuhiro; Yamashita, Kota; Shirahase, Yasushi; Sakaguchi, Kouji; Asaeda, Ayumi; Kishi, Kazuki; Schlattner, Uwe; Wallimann, Theo; Yanai, Mitsuru; Kumasaka, Kazunari

doi:10.1080/00365510902981171

Cited by 3 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We measured the serum MtCK activity according to a previously reported method [23]. Conventional assay of CK-MB activity is an immunoinhibition method against the MM fraction of creatine kinase (CK-M).…”

Section: Methodsmentioning

confidence: 99%

Mitochondrial Creatine Kinase is Decreased in the Serum of Idiopathic Parkinson’s Disease Patients

Xu¹,

Fu²,

Pan³

et al. 2019

Aging and disease

View full text Add to dashboard Cite

Mitochondrial creatine kinase (MtCK) is vital in the process of mitochondrial energy metabolism, and mitochondrial dysfunction has been implicated in the pathogenesis of Parkinson’s disease (PD). Therefore, we speculated that MtCK activity could be altered in the serum of PD patients. However, no studies to date have investigated this specific topic, so we sought to investigate the serum MtCK activities among a cohort of PD patients. 50 patients with PD and 30 age-matched controls were recruited for this study. Serum ubiquitous MtCK (uMtCK) and sarcomeric MtCK (sMtCK) activities were assayed using an immunoinhibition method. Correlations between serum uMtCK/sMtCK activities and clinical features/parameters were explored in the PD group. Our study revealed a significant decrease in the uMtCK activity in the PD group when compared with the control group. No significant difference was found in the serum sMtCK activity between the PD and control groups. There was a significant correlation between serum uMtCK activities and the disease progression rate, duration, and age at onset in PD patients. While no significant relationship was found between the serum uMtCK activities and the Hoehn & Yahr stage or main non-motor symptoms scale. There was a significant decrease in the uMtCK activity in the serum of PD patients, which was associated with the rate of disease progression, duration, and age at onset of disease. Therefore, uMtCK activity in serum offers a useful clue for identification of PD biomarkers.

show abstract

Section: Methodsmentioning

confidence: 99%

Mitochondrial Creatine Kinase is Decreased in the Serum of Idiopathic Parkinson’s Disease Patients

Xu¹,

Fu²,

Pan³

et al. 2019

Aging and disease

View full text Add to dashboard Cite

show abstract

“…The L-System CK-MB MtO (Sysmex Corporation, Kobe, Japan), a new reagent kit that can be used to measure CK-MB activity and inhibit MtCK activity, was developed recently [9,10]. Here, we evaluated the clinical usefulness of this new CK-MB reagent, which includes anti-MtCK antibodies and abrogates the effect of MtCK activity in the serum, and confirmed the clinical efficacy of inhibition of MtCK activity.…”

Section: Introductionmentioning

confidence: 56%

“…The intercept of the linear regression equation was approximately 9 U/L and appeared to correspond to MtCK activity in patient sera. MtCK activity is present in the serum of healthy individuals, and it was 3.8 U/L in an immunoinhibition assay [10]. MtCK activity in serum was calculated by subtracting CK-B activity determined using the new method from that determined using the conventional kit.…”

Section: Discussionmentioning

confidence: 99%

“…L-System CK-MB MtO is a novel CK-MB assay kit; this kit includes an anti-CK-M polyclonal antibody (goat) and 2 types of anti-MtCK monoclonal antibody (mouse) against ubiquitous MtCK (uMtCK) and sarcomeric MtCK (sMtCK) in a reagent set for determining CK activity [10]. Anti-CK-M antibody and 2 types of anti-MtCK antibody can inhibit approximately 3000 U/L CK-MM and 500 U/L MtCK, respectively.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Effect of the Inhibition of Mitochondrial Creatine Kinase Activity on the Clinical Diagnosis of Suspected Acute Myocardial Infarction

Maekawa

Sugiura²,

Iwahara³

et al. 2012

TOCCHEMJ

View full text Add to dashboard Cite

Background: Creatine kinase isoenzyme MB (CK-MB) activity using the immunoinhibition method has been measured in clinical laboratories. However, the presence of mitochondrial CK (MtCK) abnormally increases CK-MB activity when measured using the conventional method, which can lead to misdiagnosis of acute myocardial infarction (AMI). A new CK-MB activity assay kit that can inhibit MtCK activity was recently developed; here, we describe the performance of this kit. Methods: The analytical performance of this new kit was investigated using 338 samples, and the correlation between results obtained using the new and conventional kits were analyzed. Results: A good correlation (r > 0.993) was found between results obtained using the new and conventional kits in the sera from patients with obvious AMI (n = 91). However, a poor correlation exists between results obtained using the new and conventional kits in samples from patients without AMI. Electrophoretic CK isoenzyme analysis confirmed that the appearance of MtCK in nearly all samples from patients with malignant tumors makes poor correlation. Conclusion: Inhibiting MtCK activity is important for diagnosing AMI. The new method may provide a more accurate value of CK-MB activity for clinical use.

show abstract

“…MtCK activity was measured with an immune‐inhibition method using two types of anti‐MtCK monoclonal antibodies, that is, an anti‐uMtCK monoclonal antibody and an anti‐sMtCK monoclonal antibody in addition to an anticreatine kinase‐M antibody as described previously . JCA‐BM8040 (JEOL, Tokyo, Japan) was used as an automatic analyzer.…”

Section: Methodsmentioning

confidence: 99%

Increased serum mitochondrial creatine kinase activity as a risk for hepatocarcinogenesis in chronic hepatitis C patients

Enooku

Nakagawa

Soroida

et al. 2014

Intl Journal of Cancer

View full text Add to dashboard Cite

Serum mitochondrial creatine kinase (MtCK) activity was reportedly increased in cirrhotic patients although less prominent than that in hepatocellular carcinoma (HCC) patients. To elucidate the clinical significance of serum MtCK activity in chronic liver disease, 171 chronic hepatitis C patients were enrolled. Serum MtCK activity in study subjects was correlated with serum albumin, platelet counts, liver stiffness values and serum aspartate and alanine aminotransferase. In mouse fibrotic liver induced by bile duct ligation, ubiquitous MtCK mRNA and protein expressions were significantly enhanced and its immunoreactivity was increased, predominantly in hepatocytes. During the mean follow-up period of 2.7 years, HCC developed in 21 patients, in whom serum MtCK activity was significantly higher than that in patients without HCC development. Multivariate Cox regression analysis revealed that higher serum MtCK activity was a risk for HCC development. A cutoff value of MtCK for the prediction of HCC development was determined as 9.0 U/L on receiver operating characteristics analysis, where area under receiver operating characteristics curve was 0.754, with a sensitivity of 61.9%, a specificity of 92.8% and a high negative predictive value of 94.2%. Cumulative incidence of HCC was significantly higher in patients with serum MtCK activity of >9.0 U/L compared to those with serum MtCK activity of 9.0 U/L even in patients with elevated liver stiffness value, >15 kPa. In conclusion, serum MtCK activity may be increased correlatively with the stage of liver fibrosis and hepatocellular damage. Increased serum MtCK activity is an independent risk for hepatocarcinogenesis in chronic hepatitis C patients.

show abstract

Development and performance of an enzyme immunoassay to detect creatine kinase isoenzyme MB activity using anti-mitochondrial creatine kinase monoclonal antibodies

Cited by 3 publications

References 0 publications

Mitochondrial Creatine Kinase is Decreased in the Serum of Idiopathic Parkinson’s Disease Patients

Mitochondrial Creatine Kinase is Decreased in the Serum of Idiopathic Parkinson’s Disease Patients

Effect of the Inhibition of Mitochondrial Creatine Kinase Activity on the Clinical Diagnosis of Suspected Acute Myocardial Infarction

Increased serum mitochondrial creatine kinase activity as a risk for hepatocarcinogenesis in chronic hepatitis C patients

Contact Info

Product

Resources

About